Sign in and upgrade to a paid plan to export price history as CSV.

ADLINE CHEM LAB LIMITED

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524604
₹15.04
▲ 0.71 (4.95%)
Sept. 24, 2026 · BSE · bse_bhavcopy
Quality
37/100
Weak
Valuation
—/100
Data unavailable
Momentum
69/100
Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹9 Cr
PE (TTM)
Data unavailable.
Price to Book
-5.0
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
4.1
Free Cash Flow
₹-0 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
800.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
0.00%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
0.00%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-4200.00%
as of Dec. 31, 2024
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-99.03%
as of March 31, 2022
Industry median 14.05% (173 companies)
Current Ratio
3.97
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
-1.02
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-0.38
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
7405.00%
as of March 31, 2022
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
7420.00%
as of March 31, 2022
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-8.45%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-510.85%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-336.36%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
19.89%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 5 met
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (-1.02)
  • Yes Return on equity is 15% or more (19.9%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 4 met
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
5.0%
Low 15.0400 · High 15.0400
1W return
15.7%
Low 13.6500 · High 15.0400
1M return
34.9%
Low 11.5200 · High 15.0400
52W return
4.1%
Low 10.6300 · High 15.0900
Lifetime High ₹28.9700 (Jan. 8, 2024)
Lifetime Low ₹5.0000 (April 15, 2020)

Full price history and technicals →

EMA & SMA

Bullish4
Bearish2
5D
13.9
10D
13.3
20D
13.3
50D
15.4
100D
16.0
200D
13.4

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

15.04
Pivot
First resistance15.04
Second resistance15.04
Third resistance15.04
First support15.04
Second support15.04
Third support15.04
Day RSI58.2
Day MFI81.6
Day MACD-0.53
Day MACD signal-1.17

Beta

1M—
3M—
1Y—
3Y-0.01

Price change analysis

↑ 34.9%
Over 1 Month
LowHigh
11.5215.04
↑ 4.1%
Over 3 Months
LowHigh
10.6315.09
↑ 4.1%
Over 6 Months
LowHigh
10.6315.09
↑ 4.1%
Over 1 Year
LowHigh
10.6315.09
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (June 30, 2026)
₹0 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹0.0700

Ranks #178 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter25.85%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 25.85% in Jun 2026 qtr

All shareholding details →

Corporate Actions

Full history (1 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Kamron Laboratories Ltd. to ADLINE CHEM LAB LIMITED

All corporate actions →

Corporate Announcements

All 3 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
29 Sep 2026 AGM/EGM Adline Chem Lab Ltd - 524604 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
29 Sep 2026 Insider Trading / SAST Adline Chem Lab Ltd - 524604 - Closure of Trading Window
28 Sep 2026 AGM/EGM Adline Chem Lab Ltd - 524604 - Shareholder Meeting / Postal Ballot-Outcome of AGM

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (7405.0%)

Weaknesses

  • Negative shareholder equity (Debt/Equity -1.02) -- accumulated losses exceed paid-in capital
  • Declining revenue YoY (-99.0%)
  • Declining profit YoY (-4200.0%)

Opportunities

Data unavailable.

Threats

  • Weak interest coverage (-0.4x) -- limited cushion against rising rates

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about ADLINE CHEM LAB LIMITED

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.